Literature DB >> 22994414

Positive modulation of the α9α10 nicotinic cholinergic receptor by ascorbic acid.

J C Boffi1, C Wedemeyer, M Lipovsek, E Katz, D J Calvo, A B Elgoyhen.   

Abstract

BACKGROUND AND
PURPOSE: The activation of α9α10 nicotinic cholinergic receptors (nAChRs) present at the synapse between efferent olivocochlear fibres and cochlear hair cells can prevent acoustic trauma. Hence, pharmacological potentiators of these receptors could be useful therapeutically. In this work, we characterize ascorbic acid as a positive modulator of recombinant α9α10 nAChRs. EXPERIMENTAL APPROACH: ACh-evoked responses were analysed under two-electrode voltage-clamp recordings in Xenopus laevis oocytes injected with α9 and α10 cRNAs. KEY
RESULTS: Ascorbic acid potentiated ACh responses in X. laevis oocytes expressing α9α10 (but not α4β2 or α7) nAChRs, in a concentration-dependent manner, with an effective concentration range of 1-30 mM. The compound did not affect the receptor's current-voltage profile nor its apparent affinity for ACh, but it significantly enhanced the maximal evoked currents (percentage of ACh maximal response, 240 ± 20%). This effect was specific for the L form of reduced ascorbic acid. Substitution of the extracellular cysteine residues present in loop C of the ACh binding site did not affect the potentiation. Ascorbic acid turned into a partial agonist of α9α10 nAChRs bearing a point mutation at the pore domain of the channel (TM2 V13'T mutant). A positive allosteric mechanism of action rather than an antioxidant effect of ascorbic acid is proposed. CONCLUSIONS AND IMPLICATIONS: The present work describes one of the few agents that activates or potentiates α9α10 nAChRs and leads to new avenues for designing drugs with potential therapeutic use in inner ear disorders.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22994414      PMCID: PMC3631383          DOI: 10.1111/j.1476-5381.2012.02221.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  73 in total

1.  Regulation of fast inactivation of cloned mammalian IK(A) channels by cysteine oxidation.

Authors:  J P Ruppersberg; M Stocker; O Pongs; S H Heinemann; R Frank; M Koenen
Journal:  Nature       Date:  1991-08-22       Impact factor: 49.962

Review 2.  Ocular ascorbate transport and metabolism.

Authors:  R C Rose; A M Bode
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1991

3.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

4.  Changes in channel properties of acetylcholine receptors during the time course of thiol chemical modifications.

Authors:  C Bouzat; F J Barrantes; F J Sigworth
Journal:  Pflugers Arch       Date:  1991-03       Impact factor: 3.657

Review 5.  Ascorbic acid in the brain.

Authors:  R A Grünewald
Journal:  Brain Res Brain Res Rev       Date:  1993 Jan-Apr

Review 6.  A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission.

Authors:  G V Rebec; R C Pierce
Journal:  Prog Neurobiol       Date:  1994-08       Impact factor: 11.685

7.  Ascorbate concentration in human cerebrospinal fluid (CSF) and serum. Intrathecal accumulation and CSF flow rate.

Authors:  H Reiber; M Ruff; M Uhr
Journal:  Clin Chim Acta       Date:  1993-08-31       Impact factor: 3.786

8.  Expression of a rabbit renal ascorbic acid transporter in Xenopus laevis oocytes.

Authors:  D L Dyer; Y Kanai; M A Hediger; S A Rubin; H M Said
Journal:  Am J Physiol       Date:  1994-07

9.  Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate.

Authors:  M D Majewska; J A Bell; E D London
Journal:  Brain Res       Date:  1990-12-24       Impact factor: 3.252

10.  Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor.

Authors:  J M Sullivan; S F Traynelis; H S Chen; W Escobar; S F Heinemann; S A Lipton
Journal:  Neuron       Date:  1994-10       Impact factor: 17.173

View more
  5 in total

Review 1.  Innovative pharmaceutical approaches for the management of inner ear disorders.

Authors:  Umberto M Musazzi; Silvia Franzé; Francesco Cilurzo
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

2.  Preventing presbycusis in mice with enhanced medial olivocochlear feedback.

Authors:  Luis E Boero; Valeria C Castagna; Gonzalo Terreros; Marcelo J Moglie; Sebastián Silva; Juan C Maass; Paul A Fuchs; Paul H Delano; Ana Belén Elgoyhen; María Eugenia Gómez-Casati
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-11       Impact factor: 11.205

Review 3.  The α9α10 nicotinic acetylcholine receptor: a compelling drug target for hearing loss?

Authors:  Ana Belén Elgoyhen
Journal:  Expert Opin Ther Targets       Date:  2022-03-07       Impact factor: 6.902

4.  A 4/8 Subtype α-Conotoxin Vt1.27 Inhibits N-Type Calcium Channels With Potent Anti-Allodynic Effect.

Authors:  Shuo Wang; Peter Bartels; Cong Zhao; Arsalan Yousuf; Zhuguo Liu; Shuo Yu; Anuja R Bony; Xiaoli Ma; Qin Dai; Ting Sun; Na Liu; Mengke Yang; Rilei Yu; Weihong Du; David J Adams; Qiuyun Dai
Journal:  Front Pharmacol       Date:  2022-04-29       Impact factor: 5.988

Review 5.  Corticofugal and Brainstem Functions Associated With Medial Olivocochlear Cholinergic Transmission.

Authors:  Hernan Alvarez-Munoz; Sergio Vicencio-Jimenez; Pascal Jorratt; Paul H Delano; Gonzalo Terreros
Journal:  Front Neurosci       Date:  2022-04-27       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.